Reference SummaryWaalkes MP, Cancer Res 2006 Feb 1;66(3):1337-45
Title |
Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. | ||||
Authors |
Waalkes MP; Liu J; Ward JM; Powell DA; Diwan BA | ||||
Journal |
Cancer Res | ||||
Volume |
66 | ||||
Issue |
3 | ||||
Year |
2006 | ||||
Pages |
1337-45 | ||||
Abstract |
Transplacental inorganic arsenic carcinogenicity, together with postnatal exposure to diethylstilbestrol or tamoxifen, was studied. Pregnant CD1 mice received 85 ppm arsenic in the drinking water from gestation days 8 to 18 and were allowed to give birth. Groups (n = 35) of female offspring were injected s.c. on postpartum days 1 through 5 with diethylstilbestrol (2 microg/pup/d) or tamoxifen (10 microg/pup/d) and observed for 90 weeks. Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma. Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression. For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors. Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site. Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal tumors, and urinary bladder proliferative lesions, including three transitional cell carcinomas. Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions. Uterine and bladder carcinoma induced by arsenic plus diethylstilbestrol greatly overexpressed estrogen receptor-alpha (ER-alpha) and pS2, an estrogen-regulated gene. In neonatal uteri, prenatal arsenic increased ER-alpha expression and enhanced estrogen-related gene expression induced by postnatal diethylstilbestrol. Thus, arsenic acts with estrogens to enhance production of female mouse urogenital cancers. | ||||
Links |
J:106681 – MGI References 16452187 – National Library of Medicine/PubMed |
||||
Strain Notes
|
Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
---|---|---|---|---|---|
CD-1 | Adrenal gland - Cortex adenoma | Adrenal gland - Cortex |
3.0 |
||
CD-1 | Adrenal gland - Cortex adenoma |
|
Adrenal gland - Cortex |
26 |
|
CD-1 | Adrenal gland - Cortex adenoma |
|
Adrenal gland - Cortex |
9.1 |
|
CD-1 | Adrenal gland - Cortex adenoma |
|
Adrenal gland - Cortex |
5.7 |
|
CD-1 | Adrenal gland - Cortex adenoma |
|
Adrenal gland - Cortex |
24 |
|
CD-1 | Adrenal gland - Cortex adenoma |
|
Adrenal gland - Cortex |
20 |
|
CD-1 | Blood vessel hemangioma | Ovary |
0 |
||
CD-1 | Blood vessel hemangioma | Liver |
0 |
||
CD-1 | Blood vessel hemangioma |
|
Ovary |
8.8 |
|
CD-1 | Blood vessel hemangioma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangioma |
|
Ovary |
0 |
|
CD-1 | Blood vessel hemangioma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangioma |
|
Ovary |
0 |
|
CD-1 | Blood vessel hemangioma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangioma |
|
Ovary |
6.1 |
|
CD-1 | Blood vessel hemangioma |
|
Liver |
3.0 |
|
CD-1 | Blood vessel hemangioma |
|
Ovary |
5.7 |
|
CD-1 | Blood vessel hemangioma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangiosarcoma | Uterus |
0 |
||
CD-1 | Blood vessel hemangiosarcoma | Liver |
0 |
||
CD-1 | Blood vessel hemangiosarcoma |
|
Uterus |
2.9 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Liver |
5.9 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Uterus |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Uterus |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Uterus |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Liver |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Uterus |
0 |
|
CD-1 | Blood vessel hemangiosarcoma |
|
Liver |
2.9 |
|
CD-1 | Bone osteosarcoma |
|
Skin |
2.9 |
|
CD-1 | Intestine - Small Intestine adenoma |
|
Intestine - Small Intestine |
2.9 |
|
CD-1 | Kidney - Renal tubule hyperplasia - cystic |
|
Kidney - Renal tubule |
2.9 |
|
CD-1 | Kidney - Renal tubule hyperplasia - cystic |
|
Kidney - Renal tubule |
2.9 |
|
CD-1 | Kidney carcinoma | Kidney |
0 |
||
CD-1 | Kidney carcinoma |
|
Kidney |
0 |
|
CD-1 | Kidney carcinoma |
|
Kidney |
0 |
|
CD-1 | Kidney carcinoma |
|
Kidney |
0 |
|
CD-1 | Kidney carcinoma |
|
Kidney |
0 |
|
CD-1 | Kidney carcinoma |
|
Kidney |
2.9 |
|
CD-1 | Kidney hyperplasia | Kidney |
0 |
||
CD-1 | Kidney hyperplasia |
|
Kidney |
0 |
|
CD-1 | Kidney hyperplasia |
|
Kidney |
0 |
|
CD-1 | Kidney hyperplasia |
|
Kidney |
0 |
|
CD-1 | Leukocyte leukemia | Leukocyte |
3.0 |
||
CD-1 | Leukocyte leukemia |
|
Leukocyte |
3.0 |
|
CD-1 | Leukocyte leukemia |
|
Leukocyte |
2.9 |
|
CD-1 | Leukocyte lymphoma | Leukocyte |
30 |
||
CD-1 | Leukocyte lymphoma |
|
Leukocyte |
5.9 |
|
CD-1 | Leukocyte lymphoma |
|
Leukocyte |
9.1 |
|
CD-1 | Leukocyte lymphoma |
|
Leukocyte |
17 |
|
CD-1 | Leukocyte lymphoma |
|
Leukocyte |
12 |
|
CD-1 | Leukocyte lymphoma |
|
Leukocyte |
29 |
|
CD-1 | Liver - Bile duct cholangiocarcinoma | Liver - Bile duct |
0 |
||
CD-1 | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
2.9 |
|
CD-1 | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
0 |
|
CD-1 | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
0 |
|
CD-1 | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
0 |
|
CD-1 | Liver - Bile duct cholangiocarcinoma |
|
Liver - Bile duct |
0 |
|
CD-1 | Liver hepatocellular adenoma | Liver |
0 |
||
CD-1 | Liver hepatocellular adenoma |
|
Liver |
2.9 |
|
CD-1 | Liver hepatocellular adenoma |
|
Liver |
3.0 |
|
CD-1 | Liver hepatocellular adenoma |
|
Liver |
0 |
|
CD-1 | Liver hepatocellular adenoma |
|
Liver |
9.1 |
|
CD-1 | Liver hepatocellular adenoma |
|
Liver |
8.6 |
|
CD-1 | Liver hepatocellular carcinoma | Liver |
0 |
||
CD-1 | Liver hepatocellular carcinoma |
|
Liver |
0 |
|
CD-1 | Liver hepatocellular carcinoma |
|
Liver |
0 |
|
CD-1 | Liver hepatocellular carcinoma |
|
Liver |
0 |
|
CD-1 | Liver hepatocellular carcinoma |
|
Liver |
6.1 |
|
CD-1 | Liver hepatocellular carcinoma |
|
Liver |
0 |
|
CD-1 | Lung adenocarcinoma | Lung |
12 |
||
CD-1 | Lung adenocarcinoma |
|
Lung |
15 |
|
CD-1 | Lung adenocarcinoma |
|
Lung |
6.1 |
|
CD-1 | Lung adenocarcinoma |
|
Lung |
11 |
|
CD-1 | Lung adenocarcinoma |
|
Lung |
21 |
|
CD-1 | Lung adenocarcinoma |
|
Lung |
14 |
|
CD-1 | Lung adenoma | Lung |
15 |
||
CD-1 | Lung adenoma |
|
Lung |
21 |
|
CD-1 | Lung adenoma |
|
Lung |
9.1 |
|
CD-1 | Lung adenoma |
|
Lung |
5.7 |
|
CD-1 | Lung adenoma |
|
Lung |
6.1 |
|
CD-1 | Lung adenoma |
|
Lung |
8.6 |
|
CD-1 | Mammary gland adenocarcinoma |
|
Mammary gland |
2.9 |
|
CD-1 | Mammary gland carcinoma | Mammary gland |
3.0 |
||
CD-1 | Mesodermal cell/mesoblast myxosarcoma |
|
Mesodermal cell/mesoblast |
3.0 |
|
CD-1 | Mesodermal cell/mesoblast sarcoma | Skin |
3.0 |
||
CD-1 | Mesodermal cell/mesoblast sarcoma |
|
Skin |
3.0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma | Uterus |
0 |
||
CD-1 | Muscle - Smooth leiomyosarcoma | Uterus - Cervix |
0 |
||
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
2.9 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus - Cervix |
3.0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus |
0 |
|
CD-1 | Muscle - Smooth leiomyosarcoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Muscle - Striated - Skeletal rhabdomyosarcoma |
|
Skin |
2.9 |
|
CD-1 | Muscle - Striated - Skeletal rhabdomyosarcoma |
|
Skin |
3.0 |
|
CD-1 | Myoepithelial cell myoepithelioma - malignant |
|
Salivary gland |
3.0 |
|
CD-1 | Ovary adenoma | Ovary |
0 |
||
CD-1 | Ovary adenoma |
|
Ovary |
12 |
|
CD-1 | Ovary adenoma |
|
Ovary |
6.1 |
|
CD-1 | Ovary adenoma |
|
Ovary |
2.9 |
|
CD-1 | Ovary adenoma |
|
Ovary |
18 |
|
CD-1 | Ovary adenoma |
|
Ovary |
2.9 |
|
CD-1 | Ovary carcinoma | Ovary |
0 |
||
CD-1 | Ovary carcinoma |
|
Ovary |
0 |
|
CD-1 | Ovary carcinoma |
|
Ovary |
0 |
|
CD-1 | Ovary carcinoma |
|
Ovary |
0 |
|
CD-1 | Ovary carcinoma |
|
Ovary |
3.0 |
|
CD-1 | Ovary carcinoma |
|
Ovary |
5.7 |
|
CD-1 | Oviduct adenoma | Oviduct |
0 |
||
CD-1 | Oviduct adenoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct adenoma |
|
Oviduct |
3.0 |
|
CD-1 | Oviduct adenoma |
|
Oviduct |
2.9 |
|
CD-1 | Oviduct adenoma |
|
Oviduct |
6.1 |
|
CD-1 | Oviduct adenoma |
|
Oviduct |
8.6 |
|
CD-1 | Oviduct carcinoma | Oviduct |
0 |
||
CD-1 | Oviduct carcinoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct carcinoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct carcinoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct carcinoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct carcinoma |
|
Oviduct |
0 |
|
CD-1 | Oviduct hyperplasia | Oviduct |
15 |
||
CD-1 | Oviduct hyperplasia |
|
Oviduct |
79 |
|
CD-1 | Oviduct hyperplasia |
|
Oviduct |
73 |
|
CD-1 | Oviduct hyperplasia |
|
Oviduct |
86 |
|
CD-1 | Oviduct hyperplasia |
|
Oviduct |
79 |
|
CD-1 | Oviduct hyperplasia |
|
Oviduct |
71 |
|
CD-1 | Thyroid gland adenocarcinoma |
|
Thyroid gland |
3.0 |
|
CD-1 | Urinary bladder - Transitional cell carcinoma - undifferentiated |
|
Urinary bladder - Transitional cell |
observed |
|
CD-1 | Urinary bladder transitional cell carcinoma | Urinary bladder |
0 |
||
CD-1 | Urinary bladder transitional cell carcinoma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell carcinoma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell carcinoma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell carcinoma |
|
Urinary bladder |
9.1 |
|
CD-1 | Urinary bladder transitional cell carcinoma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell hyperplasia | Urinary bladder |
3.0 |
||
CD-1 | Urinary bladder transitional cell hyperplasia |
|
Urinary bladder |
15 |
|
CD-1 | Urinary bladder transitional cell hyperplasia |
|
Urinary bladder |
3.0 |
|
CD-1 | Urinary bladder transitional cell hyperplasia |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell hyperplasia |
|
Urinary bladder |
30 |
|
CD-1 | Urinary bladder transitional cell hyperplasia |
|
Urinary bladder |
26 |
|
CD-1 | Urinary bladder transitional cell papilloma | Urinary bladder |
0 |
||
CD-1 | Urinary bladder transitional cell papilloma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell papilloma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell papilloma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell papilloma |
|
Urinary bladder |
0 |
|
CD-1 | Urinary bladder transitional cell papilloma |
|
Urinary bladder |
2.9 |
|
CD-1 | Uterus - Cervix adenoma | Uterus - Cervix |
0 |
||
CD-1 | Uterus - Cervix adenoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix adenoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix adenoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix adenoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix adenoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix carcinoma | Uterus - Cervix |
0 |
||
CD-1 | Uterus - Cervix carcinoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix carcinoma |
|
Uterus - Cervix |
18 |
|
CD-1 | Uterus - Cervix carcinoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix carcinoma |
|
Uterus - Cervix |
24 |
|
CD-1 | Uterus - Cervix carcinoma |
|
Uterus - Cervix |
0 |
|
CD-1 | Uterus - Cervix squamous cell carcinoma |
|
Uterus - Cervix |
observed |
|
CD-1 | Uterus adenocarcinoma |
|
Uterus |
observed |
|
CD-1 | Uterus adenoma | Uterus |
0 |
||
CD-1 | Uterus adenoma |
|
Uterus |
8.8 |
|
CD-1 | Uterus adenoma |
|
Uterus |
0 |
|
CD-1 | Uterus adenoma |
|
Uterus |
0 |
|
CD-1 | Uterus adenoma |
|
Uterus |
0 |
|
CD-1 | Uterus adenoma |
|
Uterus |
0 |
|
CD-1 | Uterus carcinoma | Uterus |
0 |
||
CD-1 | Uterus carcinoma |
|
Uterus |
5.9 |
|
CD-1 | Uterus carcinoma |
|
Uterus |
0 |
|
CD-1 | Uterus carcinoma |
|
Uterus |
5.7 |
|
CD-1 | Uterus carcinoma |
|
Uterus |
21 |
|
CD-1 | Uterus carcinoma |
|
Uterus |
5.7 |
|
CD-1 | Vagina adenoma | Vagina |
0 |
||
CD-1 | Vagina adenoma |
|
Vagina |
0 |
|
CD-1 | Vagina adenoma |
|
Vagina |
0 |
|
CD-1 | Vagina adenoma |
|
Vagina |
0 |
|
CD-1 | Vagina adenoma |
|
Vagina |
0 |
|
CD-1 | Vagina adenoma |
|
Vagina |
0 |
|
CD-1 | Vagina carcinoma | Vagina |
0 |
||
CD-1 | Vagina carcinoma |
|
Vagina |
0 |
|
CD-1 | Vagina carcinoma |
|
Vagina |
3.0 |
|
CD-1 | Vagina carcinoma |
|
Vagina |
0 |
|
CD-1 | Vagina carcinoma |
|
Vagina |
15 |
|
CD-1 | Vagina carcinoma |
|
Vagina |
0 |
|
CD-1 | Vagina squamous cell carcinoma |
|
Vagina |
observed |